Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neuroblastoma 10Melanoma 8Neoplasm Metastasis 6Breast Neoplasms 6Ganglioneuroblastoma 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Carcinoma, Renal Cell 3Brain Neoplasms 3Uveal Melanoma 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia 2Gliosarcoma 2Glioma 2Carcinoma, Intraductal, Noninfiltrating 2Astrocytoma 2

Interventions

Everolimus 9Temozolomide 7Sunitinib 7Specimen Handling 4Octreotide 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4lutetium Lu 177 dotatate 3Leucovorin 3sargramostim 2montanide ISA 51 2incomplete Freund's adjuvant 2cabozantinib 2Thalidomide 2Streptozocin 2Sorafenib 2Oxaliplatin 2Irinotecan 2Injections 2Endoscopic Ultrasound-Guided Fine Needle Aspiration 2Doxorubicin 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1sapanisertib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Colony-Stimulating Factors × Clear all
NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡